Inflammation, Insulin Resistance, Metabolic Syndrome, Obstructive Sleep Apnea
Conditions
Keywords
obstructive sleep apnea, metabolic dysfunction, metabolic syndrome, adipocyte fatty acid binding protein
Brief summary
Adipocyte fatty acid binding protein (A-FABP) is a member of the FABP super family, is abundant in adipocytes and macrophages. Regulatory functions of A-FABP in lipid and glucose metabolism have been described, and it is suggested to play an important role in the pathogenesis of metabolic syndrome.We hypothesize that obstructive sleep apnea (OSA) may upregulate A-FABP production and thus causally contribute to metabolic dysfunction. Our group has recently demonstrated that A-FABP, expressed and secreted from adipocytes, is present in the blood stream .The levels of A-FABP correlated with various metabolic variates in the metabolic syndrome. Furthermore, we have obtained novel data in men with a range of sleep disordered breathing showed that the duration of oxygen desaturation correlated with circulating levels of A-FABP, independent of age and waist/body mass index. The current proposal aims to pursue this finding and further explore the role of A-FABP in the association of OSA and metabolic dysfunction.
Detailed description
We hypothesize that there are changes in circulating A-FABP level which can be mitigated by effective treatment of OSA. The aim is to investigate the effect of CPAP treatment of OSA on circulating A-FABP, and other metabolic biomarkers and cardiovascular parameters
Interventions
DEVICEcontinuous positive airway pressure
an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
Sponsors
The University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects between 18 - 65 years old * Able to understand and give informed written consent
Exclusion criteria
* BMI \> 35 kg/m2, and features of obesity hypoventilation syndrome * known diabetes mellitus or hyperlipidemia on treatment * known cardiovascular disease except hypertension stable on treatment * unstable medical illness * need for starting treatment for OSA or other medical conditions immediately
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| adipocyte fatty acid binding protein | changes over 4 weeks of CPAP treatment | blood assay |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lipids and lipoprotein | changes over 4 weeks of CPAP treatment | blood assay |
| blood Markers of oxidative stress and fat metabolism | changes over 4 weeks of CPAP treatment | — |
| Insulin and glucose | changes over 4 weeks of CPAP treatment | blood assay |
| blood pressure | changes over 4 weeks of CPAP treatment | — |
| Epworth sleepiness scale | changes over 4 weeks of CPAP treatment | by sleep questionnaire |
| blood inflammatory markers | changes over 4 weeks of CPAP treatment | — |
Countries
Hong Kong
Outcome results
None listed